TNFRSF17 and non-Hodgkin lymphoma: Fifty-eight patients (80.6%) received CD19- or CD20-CARTx for non-Hodgkin lymphoma (n = 52 [72.2%]), ALL (n = 3 [4.2%]), or CLL (n = 3 [4.2%]); BCMA-CARTx was administered in 14 patients (19.4%) with multiple myeloma.